Conditions: Overactive Bladder
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: yes

Brief summary:
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index (BMI). Participants may be enrolled with mild hepatic insufficiency.

Detailed description:
This study is planned to be conducted in two parts. Part 1 of the study will include participants with moderate hepatic insufficiency and healthy participants. If Part 2 is conducted, Part 2 of the study will include participants with mild hepatic insufficiency.

Arms:
arm 1: Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg. arm 2: Participants who are healthy will receive a single oral dose of vibegron 100 mg. arm 3: Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.

Interventions: intervention 1: Vibegron
Intervention descriptions: intervention 1: 50 mg tablet, oral

Protocol document: